TCGA-68-8251-01A-11R-2296-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.660
- MYC_TARGETS_V1+0.580
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- MITOTIC_SPINDLE+0.320
- ANGIOGENESIS+0.300
- ALLOGRAFT_REJECTION+0.250
- TNFA_SIGNALING_VIA_NFKB+0.190
- UV_RESPONSE_DN+0.160
Top 10 suppressed
- FATTY_ACID_METABOLISM-0.370
- HEME_METABOLISM-0.280
- PROTEIN_SECRETION-0.270
- CHOLESTEROL_HOMEOSTASIS-0.260
- XENOBIOTIC_METABOLISM-0.250
- ADIPOGENESIS-0.210
- BILE_ACID_METABOLISM-0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.180
- PEROXISOME-0.150
- GLYCOLYSIS-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-8276-01A-11R-2296-07 | — | cohortSQ1 | 0.828 |
| 2 | TCGA-85-7699-01A-11R-2125-07 | — | cohortSQ1 | 0.786 |
| 3 | TCGA-85-8288-01A-11R-2296-07 | — | cohortSQ1 | 0.786 |
| 4 | SRR934755 | — | — | 0.786 |
| 5 | SRR975554 | — | — | 0.781 |
| 6 | TCGA-GC-A3YS-01A-11R-A23N-07 | — | — | 0.779 |
| 7 | TCGA-37-A5EM-01A-21R-A27Q-07 | — | cohortSQ1 | 0.778 |
| 8 | TCGA-CQ-A4CB-01A-11R-A24Z-07 | — | — | 0.777 |
| 9 | TCGA-85-7950-01A-11R-2187-07 | — | cohortSQ1 | 0.764 |
| 10 | 4d36189e-fe88-4cfb-970b-a51b8e9e0783 | — | — | 0.763 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.660 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.580 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.070 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.050 | Inavolisib | — uncovered |